刃天青在急性髓系白血病中的临床前活性
本研究在急性髓系白血病(AML)中探究刃天青的体外与体内作用。刃天青在AML细胞系中呈剂量依赖性诱导细胞死亡,并降低患者来源AML细胞的增殖与集落形成;在MV4-11 AML小鼠模型中,75 mg/kg每日两次给药可见抗肿瘤效应与生存期延长,且未观察到毒性。结果提示刃天青可能是一种新型实验性AML治疗药物。
要点
- 刃天青在AML细胞系中呈剂量依赖性诱导细胞死亡。
- 刃天青减少体外处理的患者来源AML细胞的增殖与集落形成。
- MV4-11 AML小鼠模型中75 mg/kg每日两次给药可见抗肿瘤效应与生存期延长,未观察到毒性。
核心结论
- 结果提示刃天青可能是一种新型的实验性急性髓系白血病治疗药物。
研究设计与样本
- 本研究为临床前研究,在体外和体内探究刃天青对急性髓系白血病(AML)的作用。
- 体内实验使用NOD/SCID IL2rγnull小鼠的MV4-11 AML皮下模型与原位模型。
主要发现
- 刃天青在AML细胞系中以剂量依赖性方式诱导细胞死亡。
- 刃天青减少体外处理的患者来源AML细胞的增殖与集落形成。
- 以降低剂量处理72小时的细胞获得更成熟的免疫表型,提示细胞分化是抗白血病效应的机制之一。
- 健康小鼠活体光学成像显示刃天青在30分钟内还原为试卤灵,2小时后不可检测,支持每日两次给药为最优。
- 在MV4-11 AML皮下与原位小鼠模型中,75 mg/kg每日两次剂量水平下可见抗肿瘤效应与生存期延长,且未观察到毒性。
关键数值与推荐
- 刃天青降低剂量处理72小时后的AML细胞获得更成熟的免疫表型。
- 健康小鼠中刃天青在30分钟内还原为试卤灵,2小时后不可检测。
- MV4-11 AML小鼠模型中有效剂量为75 mg/kg每日两次。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resazurin, a phenoxazine used in cell viability assays, acts in vitro as an anti-leukaemic compound through the production of cellular reactive oxygen species (ROS) resulting in mitochondrial dysfunction and cell death. However, the in vivo tolerance and efficacy of resazurin in cancer are unknown. In this study, we investigated the in vitro and in vivo effects of resazurin in acute myeloid leukaemia (AML). Resazurininduced cell death in a dose-dependent manner in AML cell lines and reduced proliferation and colony formation in ex vivo treated patient-derived AML cells. Cells treated with a reduced dose of resazurin for 72 h acquired a more mature immunophenotype suggesting cell differentiation as a mechanism contributing to the anti-leukaemic effect. In vivo optical imaging in healthy mice demonstrated a reduction of resazurin to resorufin within 30 min and non-detectable after 2 h, supporting dosing twice daily as optimal. In subcutaneous and orthotopic models of MV4-11 AML in NOD/SCID IL2rγnull mice, anti-tumour effects and an increased survival were found at a dose level of 75 mg/kg twice daily without observed toxicity. Our results suggest that resazurin represents a novel experimental therapeutic for the treatment of AML.
引用
- Ha TQ, Andresen V, Erikstein BS, et al. Preclinical activity of resazurin in acute myeloid leukaemia. Br J Haematol. 2024. PMID: 39582120. doi:10.1111/bjh.19872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。